1. Children with autism spectrum disorder in Manitoba: prevalence, population characteristics and psychotropic medication use.
- Author
-
Vehling, L., Brownell, M., Kaufert, J., Nickel, N. C., and Alessi-Severini, S.
- Subjects
CHILDREN with autism spectrum disorders ,DISEASE prevalence ,PSYCHIATRIC drugs ,POPULATION health - Abstract
Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disability diagnosed in an increasing number of children. Psychotropic medication use has also increased among Canadian children and may be more common among children with intellectual disabilities. However, psychotropic medications are not strongly recommended for use among children and have been associated with significant adverse events. ASD has few effective treatment options, yet psychotropic medications are used to manage challenging behaviours in some children with ASD. Objectives: This study describes ASD prevalence and use of psychotropic medications in the pediatric population of Manitoba. Populations of children with and without ASD are described and compared to determine difference in psychotropic medication use and population characteristics. Methods: Administrative data from the Repository at the Manitoba Centre for Health Policy were used to create a cohort of children born in Manitoba. Diagnoses of ASD were based on medical claim records, hospital abstracts or special education funding data. Results: Between 2010 and 2014, 3079 Manitoba children aged 0 to 14 years had an ASD diagnosis (1% prevalence). Among children with ASD aged 0 to 18 years, 80% are boys, almost 60% were diagnosed before age 5, with 85% diagnosed before age 10, and almost 50% received special education funding. Close to 50% of all children with ASD received a psychotropic prescription before age 18, compared to only 12% in the population of children in Manitoba without ASD or an intellectual disability. Children with ASD are more likely than those in the general population of children to live in Winnipeg, be involved with child welfare services and receive psychotropic medications. Conclusion: In Manitoba, ASD is diagnosed in preschool or early school years, when treatment and services can have the greatest impact on functioning. Children with ASD are more likely to use psychotropic medications and have different population characteristics when compared to children in the general population. This epidemiological information is important to understand risk factors, assess current treatment strategies and direct future intervention planning. [ABSTRACT FROM AUTHOR]
- Published
- 2016